Literature DB >> 2449210

The mechanism of action of DuP 721, a new antibacterial agent: effects on macromolecular synthesis.

D C Eustice1, P A Feldman, A M Slee.   

Abstract

Pulse labeling studies with Bacillus subtilis showed that DuP 721 inhibited protein synthesis. The IC50 of DuP 721 for protein synthesis was 0.25 micrograms/ml but it was greater than 32 micrograms/ml for RNA and DNA synthesis. In cell-free systems, DuP 721 concentrations up to 100 microM did not inhibit peptide chain elongation reactions under conditions where chloramphenicol, tetracycline and hygromycin B inhibited these reactions. Furthermore, Dup 721 did not cause phenotypic suppression of nonsense mutations suggesting that DuP 721 did not inhibit peptide chain termination. Thus, the mechanism of action of DuP 721 is at a target preceeding chain elongation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2449210     DOI: 10.1016/0006-291x(88)90723-1

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  20 in total

1.  Comparative in vitro activity of the new oxazolidinones DuP 721 and DuP 105 against staphylococci and streptococci.

Authors:  E Mini; A Novelli; T Mazzei; P Periti
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-03       Impact factor: 3.267

2.  Lack of pharmacokinetic interaction between linezolid and antacid in healthy volunteers.

Authors:  Gabriela Grunder; Yvonne Zysset-Aschmann; Florence Vollenweider; Thomas Maier; Stephan Krähenbühl; Juergen Drewe
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  Ribosomes from an oxazolidinone-resistant mutant confer resistance to eperezolid in a Staphylococcus aureus cell-free transcription-translation assay.

Authors:  R W Murray; R D Schaadt; G E Zurenko; K R Marotti
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

4.  Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound.

Authors:  J S Daly; G M Eliopoulos; S Willey; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

5.  In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections.

Authors:  C W Ford; J C Hamel; D M Wilson; J K Moerman; D Stapert; R J Yancey; D K Hutchinson; M R Barbachyn; S J Brickner
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

6.  Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis.

Authors:  D C Eustice; P A Feldman; I Zajac; A M Slee
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

7.  Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action.

Authors:  L Xiong; P Kloss; S Douthwaite; N M Andersen; S Swaney; D L Shinabarger; A S Mankin
Journal:  J Bacteriol       Date:  2000-10       Impact factor: 3.490

8.  Pharmacokinetics of linezolid in subjects with renal dysfunction.

Authors:  Michael E Brier; Dennis J Stalker; George R Aronoff; Donald H Batts; Kristi K Ryan; Margaret O'Grady; Nancy K Hopkins; Gail L Jungbluth
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

9.  In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.

Authors:  G E Zurenko; B H Yagi; R D Schaadt; J W Allison; J O Kilburn; S E Glickman; D K Hutchinson; M R Barbachyn; S J Brickner
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

10.  The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria.

Authors:  S M Swaney; H Aoki; M C Ganoza; D L Shinabarger
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.